SM
REGN icon

Sabby Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Sabby Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-202
Closed -$7.42M – 302
2016
Q4 		$7.42M Buy
202
+139
+221% +$52.9K 0.43% 39
2016
Q3 		$2.53M Buy
63
+20
+47% +$8.02K 0.09% 110
2016
Q2 		$1.5M Sell
43
-60
-58% -$23.1K 0.08% 130
2016
Q1 		$3.71M Buy
+103
New +$42.4K 0.19% 59
2015
Q3 		– Sell
-304
Closed -$15.5M – 398
2015
Q2 		$15.5M Sell
304
-802
-73% -$391K 0.57% 35
2015
Q1 		$49.9M Buy
1,106
+1,063
+2,472% +$451K 2.08% 12
2014
Q4 		$1.76K Sell
43
-227
-84% -$89.3K 0.06% 134
2014
Q3 		$9.73K Sell
270
-896
-77% -$300K 0.37% 44
2014
Q2 		$32.9M Sell
1,166
-50
-4% -$14.8K 1.41% 15
2014
Q1 		$36.5M Buy
1,216
+564
+87% +$174K 2.05% 13
2013
Q4 		$17.9M Sell
652
-349
-35% -$100K 1.14% 21
2013
Q3 		$31.3M Sell
1,001
-1,136
-53% -$299K 2.04% 12
2013
Q2 		$48.1M Buy
+2,137
New +$498K 3.21% 7

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return

Sabby Management's REGN Position: Q1 2017 in Review

Sabby Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2017, closing a stake of 162,517 shares — an estimated $59.7M sold.

Sabby Management first reported a position in REGN in Q1 2014 and held it in 7 quarters. The position peaked at $59.7M in Q4 2016. 578 funds tracked by Wall St. Rank hold REGN as of Q1 2017.

  • Sabby Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Sabby Management sold 162,517 Regeneron Pharmaceuticals shares in Q1 2017, an estimated $59.7M.
  • Sabby Management first reported a position in Regeneron Pharmaceuticals in Q1 2014 and held it in 7 quarters.
  • Sabby Management's Regeneron Pharmaceuticals position peaked at $59.7M in Q4 2016.
  • 578 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2017.

Based on Sabby Management's 13F filing for Q1 2017, filed 15 May 2017.